City

Hangzhou (1)

Hanzhou (1)

San Francisco (1)

San Leandro (1)

Overall Status

Completed (2)

Recruiting (1)

Sign in for free

Phase

phase 1 (1)

phase 3 (1)

Sponsor

Shanghai Bovax Biotechnology Co., Ltd. (2)

University of California, Los Angeles (1)

Collaborator

Chongqing Bovax Biopharmaceutical Co., Ltd. (2)

National Cancer Institute (NCI) (1)

National Institutes of Health (NIH) (1)

Intervention

9-valent hpv recombinant vaccine (1)

9-valent hpv vaccine (1)

placebo (1)

Study Documents

Intervention Type

biological (2)

Funder Type

Industry (2)

Other (1)

Study Type

Interventional (2)

Observational (1)

cin 3

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

HPV Infections, Cervical Cancer, Vulvar Cancer Trial in Hangzhou (9-valent HPV vaccine)

Recruiting

HPV Infections
+14 more

9-valent HPV vaccine

Hangzhou, China

Huakun Lv

Feb 23, 2022

Cervical Cancers, Vulvar Cancer, Vaginal Cancer Trial in Hanzhou (9-valent HPV Recombinant Vaccine, Placebo)

Completed

Cervical Cancers
+14 more

9-valent HPV Recombinant Vaccine
Placebo

Hanzhou, China

Zhejiang Provincial Center for Disease Control and Prevention

Jan 20, 2020

HPV From Infection to Neoplasia in Adolescents and Young Women

Completed

Human Papillomavirus
+2 more

San Francisco, California
+1 more

May 13, 2016